Benzinga | Jun 15, 2021 09:23AM EDT

Brainstorm Cell Therapeutics Announces Grant Of Multiple Patents For NurOwn

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant and/or allowance of a series of patents and patent applications. These patents and patent applications, which were granted/allowed in 2020 and 2021, are expected to provide broad protection for Brainstorm's proprietary NurOwn(r) (MSC-NTF cells) technology in territories including the U.S., E.U., Canada, Israel and Hong Kong.